Alefacept in the Treatment of Psoriasis in Patients for Whom Conventional Therapies Are Inadequate

P.C.M. van de Kerkhof; Christopher Em Griffiths; Enno Christophers; M. Lebwohl; Gerald G. Krueger

doi:10.1159/000087020

Abstract

1 min read

The efficacy, quality of life effects and safety of alefacept in patients who were not candidates for conventional systemic psoriasis therapies or phototherapy were similar to those reported previously for the overall alefacept-treated population in the phase III studies.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2000

Therapeutic strategies for psoriasis

Darren M. Ashcroft, A. Li Wan Po, Christopher Em Griffiths

Article2014

Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes

Zenas Z N Yiu, Richard B. Warren, Ulrich Mrowietz, Christopher Em Griffiths

Article2003

Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.

Jean-Paul Ortonne, Mark Lebwohl, Christopher Em Griffiths

Article2019

Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE)

Richard B. Warren, Johnathan Barker, A.Y. Finlay, A. David Burden, Brian Kirby, Y. Armendáriz, R Williams, C. Hatchard, Swarna Khare, Christopher Em Griffiths

Article2004

Biological therapies in the systemic management of psoriasis: International Consensus Conference

Wolfram Sterry, Juliet N. Barker, Wolf‐Henning Boehncke, J.D. Bos, Sergio Chimenti, Enno Christophers, M. de la Brassinne, Christopher Em Griffiths, Andreas Katsambas, Knud Kragballe, Charles Lynde, Alan Menter, J.‐P. Ortonne, Kim Papp, Jörg C. Prinz, Berthold Rzany, J.R. Rönnevig, J.‐H. Saurat, Mona Ståhle, Fernando Stengel, P.C.M. van de Kerkhof, John J. Voorhees